Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathyRecruitingPhase 22026-10-09NCT07421167

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Astera Cancer CenterEast BrunswickUnited States3
Avera Cancer InstituteSioux FallsUnited States1
Baptist MD Anderson Cancer CenterJacksonvilleUnited States72
DH Cancer Research Center LLCMargateUnited States2
Highlands Oncology GroupFayettevilleUnited States16
Hope And Healing CareHinsdaleUnited States3
Intermountain HealthcareBillingsUnited States2
Mayo Clinic RochesterRochesterUnited States133
Montefiore Medical CenterThe BronxUnited States198
Pontchartrain Cancer CenterCovingtonUnited States6
Stamford HospitalStamfordUnited States7
Summit Medical GroupSummitUnited States2
University Health Kansas CityKansas CityUnited States1
University of MiamiMiamiUnited States327
Utah Cancer SpecialistsSalt Lake CityUnited States29
Yale Cancer CenterNew HavenUnited States31